11
Participants
Start Date
April 20, 2023
Primary Completion Date
July 21, 2023
Study Completion Date
July 21, 2023
Newborn Screening Assay
"The assay developed in this study is determined to be FDA regulated as an exempt diagnostic device. In this study, the testing involved with this assay fulfills the following criteria:~* Is noninvasive~* Does not require an invasive sampling procedure that presents significant risk (the finger prick is minimal risk)~* Does not by design or intention introduce energy into a subject, and~* Is not used as a diagnostic procedure without confirmation of the diagnosis by another, medically established diagnostic product or procedure, as participants will not receive results in this study."
University of Wisconsin School of Medicine and Public Health, Madison
Ultragenyx Pharmaceutical Inc
INDUSTRY
University of Wisconsin, Madison
OTHER